Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data

The development of targeted therapies over the past two decades has led to a dramatic change in the management of -mutant non-small cell lung cancer (NSCLC). While there are currently five approved EGFR tyrosine kinase inhibitors (TKIs) for treating -mutant NSCLC in the first-line setting, therapy s...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-01, Vol.15 (3), p.629
Main Authors: Marin-Acevedo, Julian A, Pellini, Bruna, Kimbrough, ErinMarie O, Hicks, J Kevin, Chiappori, Alberto
Format: Article
Language:English
Subjects:
Central nervous system
Chemotherapy
Clinical trials
Enzyme inhibitors
Epidermal growth factor receptors
Lung cancer
Metastases
Mutants
Mutation
Non-small cell lung carcinoma
Protein-tyrosine kinase
Review
Small cell lung carcinoma
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of targeted therapies over the past two decades has led to a dramatic change in the management of -mutant non-small cell lung cancer (NSCLC). While there are currently five approved EGFR tyrosine kinase inhibitors (TKIs) for treating -mutant NSCLC in the first-line setting, therapy selection after progression on EGFR TKIs remains complex. Multiple groups are investigating novel therapies and drug combinations to determine the optimal therapy and treatment sequence for these patients. In this review, we summarize the landmark trials and history of the approval of EGFR TKIs, their efficacy and tolerability, and the role of these therapies in patients with central nervous system metastasis. We also briefly discuss the mechanisms of resistance to EGFR TKIs, ongoing attempts to overcome resistance and improve outcomes, and finalize by offering treatment sequencing recommendations.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15030629